Skip to main content

Organon & Co.

corporate_fare Company Profile

Organon & Co.

OGN·NYSE·Life Sciences·CIK 0001821825

Organon & Co. is a global healthcare company focused on delivering impactful medicines and solutions for a healthier every day. The company offers a portfolio of over 70 products across women's health and general medicines, including biosimilars. Organon addresses health needs that uniquely, disproportionately, or differently affect women and expands access to essential treatments in over 140 countries and territories. Products are sold through various channels, including drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon operates six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom. The company's operations include two main product portfolios: Women's Health: This portfolio consists of prescription products primarily in contraception and fertility. Key contraception brands include Nexplanon® (etonogestrel implant), sold as Implanon NXT™ in some countries outside the United States, and NuvaRing® (etonogestrel / ethinyl estradiol vaginal ring). Nexplanon is a long-acting reversible contraceptive. Key fertility brands include Follistim AQ® (follitropin beta injection), marketed in most countries outside the United States as Puregon™. The Jada® System, intended for abnormal postpartum uterine bleeding or hemorrhage, was divested to Laborie Medical Technologies Corporation in January 2026. General Medicines: This portfolio includes biosimilars and established brands. The current biosimilars portfolio covers immunology and oncology-related treatments. Oncology biosimilars, including Ontruzant® (trastuzumab-dttb), Aybintio™ (bevacizumab), Bildyos® (denosumab-nxxp), and Bilprevda® (denosumab-nxxp), have been launched in more than 20 countries.

Organon & Co. (NYSE:OGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for OGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-30, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 10 rated 8 or above. Recent SEC coverage for OGN spans 10-Q, 8-K, DEFA14A, PREM14A.

Recent high-impact activity:

  • Organon Q3 Revenue Slips 2% to $1.57B as Sun Pharma $14.00 Deal Nears Early-2027 Close
  • Sun Pharma Prices Rs 10,000 Cr Bond Sale to Refinance Organon Deal Bridge Loans
  • Organon's Hormone-Free IUD Shows 6-Year Efficacy; FDA Review of Extended Use Underway
  • Organon Q2 2026: Material Weaknesses Remediated, Cash Surges to $1.1B on Jada Sale
  • Organon Shareholders Approve $14/Share Sun Pharma Buyout with 98.7% Vote

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$6.22B
Net Income
$187M
Diluted EPS
$0.72
Op. Cash Flow
$700M
Free Cash Flow
$538M
Gross Profit
$3.31B
Cash & Equivalents
$574M
Total Debt
$8.64B
Debt / Equity
11.49×
Net Margin
3.0%
Shares Outstanding
260.32M sh
Source: 10-K · filed 2026-02-24 · accession 0001628280-26-011125

Short Interest & Short Volume

8.48 days to cover

FINRA reported short interest of 19,693,671 shares in OGN as of the October 30, 2026 settlement, a 4.7% increase from the prior period — about 8.5 days to cover at its recent average daily volume. On November 20, 2026, 62.4% of OGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)19,693,671 shares as of October 30, 2026
Change vs prior period▲ 4.7%
Days to cover8.48 at avg daily volume of 2,322,583
Daily short volume (FINRA facilities)62.4% of 947,800 shares on November 20, 2026
5-day average short volume47.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with O →
$13.89
52-week range · as of 2026-10-30 $5.69 – $13.89
Market cap
$3.65B
Volume
3.6M (1.3× avg)
3-mo avg 2.7M
Live data · 2026-11-21 22:32 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OGN - Latest Insights

OGN
Oct 30, 2026, 8:03 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.83
Real-time Price: $13.89 info
Change: +$0.0597 (+0.43%) info
Market Cap: $3.648B info
OGN
Oct 21, 2026, 6:32 AM EDT
Source: Businessworld
Importance Score:
7
Price at Filing: $13.74
Real-time Price: $13.89 info
Change: +$0.150 (+1%) info
Market Cap: $3.648B info
OGN
Oct 16, 2026, 7:30 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.77
Real-time Price: $13.89 info
Change: +$0.1208 (+0.88%) info
Market Cap: $3.648B info
OGN
Jul 31, 2026, 8:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $13.53
Real-time Price: $13.89 info
Change: +$0.360 (+3%) info
Market Cap: $3.648B info
OGN
Jul 24, 2026, 1:42 AM EDT
Source: Moneycontrol
Importance Score:
8
Price at Filing: $13.56
Real-time Price: $13.89 info
Change: +$0.330 (+2%) info
Market Cap: $3.648B info
OGN
Jul 23, 2026, 5:13 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.56
Real-time Price: $13.89 info
Change: +$0.330 (+2%) info
Market Cap: $3.648B info
OGN
Jul 17, 2026, 4:12 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $13.52
Real-time Price: $13.89 info
Change: +$0.370 (+3%) info
Market Cap: $3.648B info
OGN
Jul 17, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.52
Real-time Price: $13.89 info
Change: +$0.370 (+3%) info
Market Cap: $3.648B info
OGN
Jul 17, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.52
Real-time Price: $13.89 info
Change: +$0.370 (+3%) info
Market Cap: $3.648B info
OGN
Jun 10, 2026, 8:40 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $13.38
Real-time Price: $13.89 info
Change: +$0.510 (+4%) info
Market Cap: $3.648B info
OGN
Jun 01, 2026, 6:03 AM EDT
Filing Type: PREM14A
Importance Score:
8
Price at Filing: $13.34
Real-time Price: $13.89 info
Change: +$0.550 (+4%) info
Market Cap: $3.648B info
OGN
May 19, 2026, 3:26 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $13.43
Real-time Price: $13.89 info
Change: +$0.460 (+3%) info
Market Cap: $3.648B info
OGN
May 07, 2026, 10:02 AM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $13.38
Real-time Price: $13.89 info
Change: +$0.515 (+4%) info
Market Cap: $3.648B info
OGN
May 04, 2026, 8:46 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $13.27
Real-time Price: $13.89 info
Change: +$0.620 (+5%) info
Market Cap: $3.648B info
OGN
Apr 30, 2026, 7:50 AM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $13.30
Real-time Price: $13.89 info
Change: +$0.590 (+4%) info
Market Cap: $3.648B info
OGN
Apr 30, 2026, 7:48 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.29
Real-time Price: $13.89 info
Change: +$0.5997 (+5%) info
Market Cap: $3.648B info
OGN
Apr 27, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $13.05
Real-time Price: $13.89 info
Change: +$0.8405 (+6%) info
Market Cap: $3.648B info
OGN
Apr 26, 2026, 7:51 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $11.31
Real-time Price: $13.89 info
Change: +$2.58 (+23%) info
Market Cap: $3.648B info
OGN
Apr 24, 2026, 4:35 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $11.45
Real-time Price: $13.89 info
Change: +$2.44 (+21%) info
Market Cap: $3.648B info
OGN
Apr 24, 2026, 4:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $11.41
Real-time Price: $13.89 info
Change: +$2.48 (+22%) info
Market Cap: $3.648B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets